个人简介

Dr Skelding is an early career researcher, who was appointed to a full-time continuing lecturing position at the start of 2012. Her research focuses on understanding cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics. If these processes can be better understood, new targeted anti-cancer therapies can be discovered. Dr Skelding's PhD investigated the use of oncolytic viruses as novel anti-cancer agents, and was funded by a National Breast Cancer Foundation (NBCF) Scholarship, as well as the commercial company, Viralytics Ltd. During her PhD, Dr Skelding developed new clinically relevant mouse models of spontaneously metastasising breast cancer, which allowed her to examine the pre-clinical effectiveness of novel viral therapies for cancer, both as single agents, and in combination with currently approved chemotherapeutic agents. Additionally, the research undertaken throughout Dr Skelding's PhD has led to the commencement of a Phase II clinical trial in the use of this virus (CAVATAK) as an intravenous treatment for melanoma, breast, and prostate cancer. In her post-doctoral studies, Dr Skelding further applied her background in cell biology to examine signal transduction pathways and the role of targeting in regulating CaMKII (calcium/calmodulin-stimulated protein kinase II) function in neuronal cells. Since completing her post-doctoral studies in 2012, she has established her own research group that focuses on better understanding cell signalling in cancer, with a view to developing new therapies that are cancer cell-specific and suitable for the treatment of a range of cancers, with a focus on leukaemias (specifically acute myeloid leukaemia, and childhood acute lymphoblastic leukaemia), breast cancer and prostate cancer. Dr Skelding has received several awards throughout her research career, including the International Society for Neurochemistry Travel Award (2011), Best Early Career Researcher Speaker at the Hunter Medical Research Institute Cancer Research Program Symposium (2010), Best Speaker at the University of Newcastle Graduate Student’s Day (2006), University Medal in Biomedical Science (2003), the University of Newcastle Vice Chancellor’s Award for Academic Excellence (2000), and numerous undergraduate and post-graduate training scholarships. Due to work completed throughout her PhD, the Hon Roslyn Kelly (Chair of the National Breast Cancer Foundation Board of Trustees) nominated Dr Skelding for a Fresh Science Award in 2006, for which she was short-listed. Dr Skelding's overarching research aim is improve patient outcomes and quality of life, by translating her research findings into the clinic.

研究领域

Medical Biochemistry

Dr Skelding's research interests focus on examining signal transduction pathways and the role of targeting in regulating cancer cell proliferation, invasion/migration and chemotherapy resistance, so that new targets for controlling these cellular functions can be identified. Using a variety of molecular, biochemical and cellular techniques (including siRNA and overexpression transfection of cancer and normal cell lines, western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, proliferation assays, cell survival assays, flow cytometry, invasion and migration assays), she has identified new pathways involved in these processes. Additionally, she has developed novel inhibitors that can target these pathways. Dr Skelding is currently examining the efficacy of these new drugs in a range of cancer types, including acute myeloid and lymphoblastic leukaemia, breast cancer and prostate cancer.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

2016 Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.', Oncotarget, (2016) 2014 Skelding KA, Arellano JM, Powis DA, Rostas JA, 'Excitotoxic stimulation of brain microslices as an in vitro model of stroke.', J Vis Exp, e51291 (2014) [C1] 2014 Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1] 2014 Abdul Majeed ABB, Pearsall E, Carpenter H, Brzozowski J, Dickson PW, Rostas JAP, Skelding KA, 'CaMKII Kinase Activity, Targeting and Control of Cellular Functions: Effect of Single and Double Phosphorylation of CaMKIIa', Calcium Signaling, 1 36-51 (2014) [C1] 2014 Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3] 2013 Skelding KA, Majeed ABA, Carpenter H, Dickson PW, Rostas JA, 'Can functional outcomes of CaMKII double phosphorylation be predicted from outcomes following single phosphorylation of CaMKII?', JOURNAL OF NEUROCHEMISTRY, 125 162-162 (2013) [E3] 2012 Rostas JAP, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is differentially regulated in striatum and cortex.', J Neurochem, 61 (2012) 2012 Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3] 2012 Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is Differentially Regulated in Striatum and Cortex', JOURNAL OF NEUROCHEMISTRY, 123 63-63 (2012) [E3] 2012 Majeed ABA, Rostas JAP, Carpenter H, Dickson PW, Skelding KA, 'Multi-site phosphorylation of CaMKII regulates CaMKII function co-operatively', JOURNAL OF NEUROCHEMISTRY, 123 116-116 (2012) [E3] 2012 Skelding KA, Barry RD, Shafren DR, 'Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride', Investigational New Drugs, 30 568-581 (2012) [C1] 2012 Skelding KA, Spratt NJ, Fluechter L, Dickson PW, Rostas JA, 'alpha CaMKII is differentially regulated in brain regions that exhibit differing sensitivities to ischemia and excitotoxicity', Journal of Cerebral Blood Flow and Metabolism, 32 2181-2192 (2012) [C1] 2011 Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1] 2010 Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1] 2009 Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, 110, Suppl. 2 42 (2009) [E3] 2009 Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, 110, Suppl. 2 40-41 (2009) [E3] 2009 Skelding KA, Barry RD, Shafren DR, 'Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21', Breast Cancer Research and Treatment, 113 21-30 (2009) [C1] 2009 Skelding KA, Rostas JA, 'Regulation of CaMKII in vivo: The importance of targeting and the intracellular microenvironment', Neurochemical Research, 34 1792-1804 (2009) [C1] 2008 Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, 106 51 (2008) [E3]